Study of eye injections with or without curcumin for diabetic eye swelling
Part of Eyes & vision, Heart & circulation, Hormones & metabolism clinical trials.
This trial tests whether adding oral curcumin (a natural supplement) to standard eye injections (bevacizumab) improves treatment for diabetic macular edema, a swelling in the back of the eye that can affect vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have diabetic macular edema with central retinal thickness over 300 microns on an OCT scan.
- You have not had bevacizumab eye injections in the last 3 months or steroid eye injections in the last 6 months.
- Your best corrected vision is at least 20/400 (not legally blind).
- You do not have other retinal diseases like uveitis or vein occlusion, or conditions like glaucoma, vitreous hemorrhage, or age-related macular degeneration.
- You are not pregnant or breastfeeding, and have no allergy to curcumin or use of warfarin.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study compares a new eye injection (RC28-E) with the standard treatment (aflibercept) for diabetic macular edema, which is swelling in the central retina that affects vision. It aims to see whether the new treatment works as well and is safe.
This Phase 1 study tests the safety and early effectiveness of OCU200 eye injections in people with diabetic macular edema (DME) that affects the center of vision. It may help by reducing the eye swelling that blurs vision from diabetes.
This trial tests an investigational drug called CU06-1004 for people with diabetic macular edema (swelling in the center of the retina caused by diabetes). It aims to see if the drug can improve vision and reduce swelling.
This trial tests an experimental medication (BI 1815368) given as an eye injection for people with diabetic macular edema, a condition where fluid builds up in the center of the retina and blurs vision. The study aims to see if this new treatment can reduce swelling and improve vision.
This trial tests if a new medicine (MK-8748) works as well as or better than the usual treatment (aflibercept) for people with diabetic macular edema, a condition that causes vision loss from diabetes-related swelling in the back of the eye.
This study tests different doses of a new medicine (BI 3812465) injected into the eye to treat diabetic macular edema—swelling in the back of the eye caused by diabetes that can blur vision. The trial measures how safe the medicine is and how well patients tolerate it.
Hear when a new Diabetic Macular Edema trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.